Bob Cuddihy, Capsida
A new gene therapy player debuts in LA with 2 startup VCs at its back, AbbVie on board with a $90M cash upfront and big plans to upend the field
These days, news of a biotech breaking out of stealth mode with a healthy launch round is not all that unusual. But Capsida just might …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
